bVP24 binds to KPNA1, KPNA5, and KPNA6 with reduced affinities in comparison to eVP24 and rVP24. The dissociation constants (K D ) for eVP24, rVP24, and bVP24 interaction with KPNAs were quantified with biolayer interferometry (BLI) (see Fig. S1 in the supplemental material). eVP24 bound KPNA1, KPNA5, and KPNA6 with dissociation constants of 13.3 Ϯ 3.9 nM, 9.77 Ϯ 1.2 nM, and 5.33 Ϯ 1.5 nM, respectively ( Table 1 ). The affinities of bVP24 for the three KPNAs were 5-fold to 10-fold weaker than those of eVP24, binding KPNA1 with a K D of 69.7 Ϯ 11 nM, KPNA5 with a K D of 43.3 Ϯ 7.1 nM, and KPNA6 with a K D of 49.0 Ϯ 4.2 nM ( Table 1 ). The affinities of rVP24 for KPNA1, KPNA5, and KPNA6, at 5.23 Ϯ 2.6 nM, 7.07 Ϯ 2.5 nM, and 3.17 Ϯ 1.3 nM, respectively, were similar to those of eVP24 (Table 1) . The effect of expressing HA-tagged eVP24, rVP24, or bVP24 on IFN-␤-induced expression of an ISG54 promoter reporter gene was assessed. Cells were transfected with empty vector (E) or 100 ng, 10 ng, or 1 ng of VP24 expression plasmid (decreasing concentrations are indicated by the wedges), an ISG54 promoter-firefly luciferase reporter plasmid, and a constitutively expressed Renilla luciferase plasmid. IFN-␤ was added after an overnight incubation, and luciferase values were measured 24 h later. Columns are representative of the means and error bars represent the standard deviations of results from two biological replicates each, including three technical replicates of each condition. Statistical significance was assessed by Student's t test. For eVP24 at 100 ng versus rVP24 at 100 ng, the single asterisk (*) represents P ϭ 0.029; for eVP24 at 10 ng versus bVP24 at 10 ng, double asterisks (**) represent P ϭ 0.0054; for eVP24 at 100 ng versus bVP24 at 100 ng, the single asterisk (*) represents P ϭ 0.0276. (B) Cell lysates from the experiment whose results are shown in panel A were assayed by Western blotting for HA-VP24 expression (anti-HA) and ␤-tubulin expression (anti-TubB). was assessed. While bVP24 efficiently inhibited ISG54 reporter activity at higher concentrations, the level of this inhibition was reduced more quickly than that seen with eVP24 or rVP24 at lower concentrations of the protein ( Fig. 2A ). rVP24 functional activity was similar to that of eVP24, consistent with the KPNA binding data ( Fig. 2A ) and data from a previous study (19) . These findings are consistent with a model where the lower bVP24 binding affinity for KPNAs results in less-efficient IFN inhibition. However, it should also be noted that bVP24 once again appeared to accumulate to lower levels than did eVP24 and rVP24 (Fig. 2B ). bVP24 displays a shorter half-life than eVP24. Next, VP24 half-life was quantified in the absence or presence of interacting KPNAs. Transfected cells were treated with an inhibitor of protein synthesis, cycloheximide (CHX), and protein lysates were examined for VP24 expression at several time points. Protein was followed over an 8-h time period (Fig. 3) , and Western blot signals were quantified and plotted (Fig. 4) . In the absence of KPNA overexpression, eVP24 levels modestly decreased by 8 h post-CHX addition. This loss of signal was mostly reversed when KPNA1, KPNA5, or KPNA6 was coexpressed ( Fig. 3A and 4A ). In contrast, expression of noninteracting KPNA2 did not result in increased eVP24 half-life ( Fig. 3B and 4A ). bVP24 exhibited a shorter half-life in comparison to eVP24, and its stability also increased upon coexpression of the NPI-1 
FIG 4
Densitometric analysis demonstrates that KPNA expression modulates eVP24 and bVP24 stability. VP24 abundance over time was measured relative to time zero, and half-live values were calculated by measuring the band intensity using Bio-Rad Image Lab software. VP24 band intensity over time was normalized to ␤-tubulin band intensity. The dotted black line indicates the 50% point. Data points represent two biological replicates. Protein half-life was calculated by the best-fit curve to the data points. Half-life decay curves for bVP24 (A), eVP24 (B), and rVP24 (C) are shown.
VP24-Karyopherin Alpha Affinities
Journal of Virology subfamily KPNAs ( Fig. 3C and 4B) but not KPNA2 ( Fig. 3D and 4B ). Interestingly, rVP24 levels in the absence of KPNA overexpression were high at the beginning of the time course but did drop over time. rVP24 remained relatively stable in the presence of KPNA1, KPNA2, or KPNA6. However, total levels were lower and stability was decreased in the presence of KPNA5 in both experiments ( Fig. 3E and F and 4C ). These data suggest that interactions with KPNAs can modulate VP24 stability.
To address the hypothesis that the lower KPNA binding affinity might account for the instability of VP24 in the absence of overexpressed KPNA and for its enhanced stability upon KPNA expression, we tested the half-live values of previously described eVP24 mutants with decreased KPNA binding affinities (21) . eVP24 cluster 1A and 1C mutants were previously shown by coimmunoprecipitation to be substantially impaired for interaction with KPNA5 (21), while eVP24 cluster 1D mutant weakly interacted with KPNA5 ( Fig. 5A) . As shown by BLI, weak binding between the three eVP24 cluster mutants and KPNA1, KPNA5, and KPNA6 occurred at the highest concentration (2 M) of eVP24 tested; however, a steady-state dissociation constant could not be determined, indicating dissociation constants for the mutant eVP24s much larger than those for the wild-type (WT) eVP24 (Fig. S2 ). The eVP24 mutants had a shorter half-life than WT eVP24, with the eVP24 cluster 1A mutant exhibiting the most rapid loss of signal (Fig. 5B) . Coexpressed with KPNA5, the half-life of eVP24 cluster 1A mutant was substantially extended, whereas expression of KPNA2, which does not interact, failed to enhance eVP24 cluster 1A mutant stability (Fig. 5C) . A separate experiment, performed to quantify the levels of the different VP24s, substantiated these conclusions (Fig. 5D ). These data suggest that binding to KPNA protects eVP24 from degradation and that weaker binding of eVP24 to KPNA can be compensated for with increased expression of KPNA.
To further correlate KPNA binding with VP24 half-life, the stabilities of eVP24 and bVP24 were compared in the absence or presence of WT or mutant KPNA5s that were previously described as being diminished for eVP24 interaction. The KPNA mutants tested included F484A, Y477G, or the KPNA5 ARM10 mutant containing four amino acid changes ( Fig. 6A ) (21). As described above, eVP24 was once again more stable than bVP24 (Fig. 6B) . The levels of expression of the KPNA5 mutants were similar over the 8-h CHX treatment (Fig. 6C) . In contrast to the outcome seen when WT KPNA5 was expressed, the interaction-defective KPNAs did not enhance bVP24 stability (Fig. 6D) . For eVP24, which is already relatively stable, expression of WT KPNA5 once again resulted in modestly enhanced stability whereas, particularly for the ARM10 KPNA5 mutant, eVP24 stability was clearly lower (Fig. 6E) .
To address the impact of endogenous KPNA expression on VP24 stability, we measured VP24 half-life in cells that were transfected with small interfering RNAs (siRNAs) targeting the NPI-1 KPNA subfamily. siRNAs specific for KPNA1, KPNA5, and KPNA6 (si3xRNA) were simultaneously transfected into cells followed by the sequential transfection of VP24 24 h later. As a negative control, cells were transfected with a nonspecific siRNA (siScramble). Only reduction of KPNA5 and KPNA6 was achieved in the cells transfected with siRNAs targeting all three NPI-1 subfamily KPNAs (Fig. 7A) . Despite the expression of endogenous KPNA1 in these cells, the eVP24 and bVP24 half-live values were reduced in comparison to those seen with the cells transfected with siScramble ( Fig. 7B and C) . rVP24 protein stability was also reduced modestly (Fig.  7D) . Together, these data suggest that endogenous KPNA levels modulate VP24 stability.
Molecular basis for differential KPNA binding by eVP24 and bVP24. We next sought to clarify the basis for the differential levels of KPNA binding by bVP24 and eVP24. Although bVP24 and eVP24 are highly conserved (86% identity at the amino acid level), analysis of the eVP24/KPNA5 structure indicated that several nonconserved residues are located at the interface (Fig. 8A to C) . To identify nonconserved residues located in hot spots for association between eVP24 and KPNA5, the cocrystal structure of eVP24 and KPNA5 C terminus (PDB 4U2X) was analyzed by HyPare (http://bip.weizmann.ac.il/HyPare), an algorithm that calculates the impact of mutations on the affinity between two interacting proteins (23) . This process identified eVP24 residues N135, R140, and V141 (bVP24 residues Q135, H140, and A141) (Fig. 8D) .
To examine the contribution of these residues to the differential levels of affinity of eVP24 and bVP24 for KPNAs, we mutated eVP24 residues at positions 135, 140, and 141 to the analogous residues found in bVP24. We also performed the reciprocal mutagenesis, making bVP24 more eVP24-like. An additional nonconserved residue at position 83 was also included in this analysis. We therefore generated mutants eVP24 4x (eVP24 P83S/N135Q/R140H/V141A) and bVP24 4x (bVP24 S83P/Q135N/H140R/A141V) ( Table 2 ). The affinities of these two mutant proteins for the three KPNAs, as determined by BLI, were similar to those of the WT VP24 proteins (Fig. S3). eVP24 4x (Tables 1 and 2 ). This suggests that, although three of these residues were identified by HyPare analysis to be important for the interaction between eVP24 and KPNA5, they do not determine the differing affinities of eVP24 and bVP24 for the KPNAs. To verify that these residues were important for the interaction of VP24 with KPNA, we mutated positions 83, 135, and 140 to alanine and position 141 to glycine, generating eVP24 4xA (eVP24 P83A/N135A/R140A/V141G) and bVP24 4xA (bVP24 S83A/Q135A/H140A/A141G). The affinities of these mutants for KPNA1, KPNA5, and KPNA6 were tested using BLI (Fig. S3) . A significant decrease in affinity for all three KPNA proteins in comparison to the WT level was detected, with eVP24 4xA binding the three KPNAs with 8-fold to 16-fold-lower affinity than WT eVP24 and bVP24 4xA binding the KPNAs with 7-fold-lower affinity than WT bVP24. This indicates that one or more of these residues are important for the interaction of VP24 and KPNA (Table 2) . Together, these data suggest that while the interaction between VP24 proteins and KPNA is evolutionarily conserved across members of the Ebolavirus genus, there is a level of plasticity and redundancy allowed in the amino acids present in these positions.
Next, we tested the effect of mutating residues at positions 83, 135, 140, and 141 on eVP24 and bVP24 IFN inhibition. The mutants included eVP24 4x, eVP24 4xA, eVP24 N135Q, bVP24 H140R/A141V, bVP24 Q135N, and bVP24 R184Q (Fig. 9A and B) . The bVP24 R184Q mutant was included in these studies because this residue is located in the eVP24 cluster 2 KPNA binding interface and is not conserved between eVP24 and bVP24 (Fig. 8C ). Cells were transfected with an ISG54 reporter plasmid and empty vector or HA-tagged VP24 proteins as indicated and treated with IFN-␤, after which reporter activity was assessed. While eVP24 4x inhibited ISG54 reporter activity to a level similar to that seen with WT eVP24 at the highest concentration, this inhibition decreased more rapidly as VP24 levels were reduced (Fig. 9C) . Mutation of the four positions in eVP24 4xA resulted in a loss of inhibition compared to WT eVP24, even at the highest concentration (Fig. 9C) . bVP24 mutant H140R/A141V behaved like WT bVP24 (Fig. 9D) , consistent with the minimal impact of these residues on binding affinities when combined in the bVP24 4xA mutant. Likewise, bVP24 R184Q inhibited ISG54 activity similarly to WT bVP24 (Fig. 9D) . The single point mutation Q135N resulted in a modest gain of inhibitory activity for bVP24, despite the lack of increased binding affinity for the KPNAs or of an obvious change in expression levels ( Fig. 9D and Table  2 ). Conversely, the reciprocal N135Q mutation did not decrease eVP24 inhibitory activity (Fig. 9C ). This suggests that in vitro binding data may not fully account for the IFN inhibitory activities of VP24s.
DISCUSSION
In this study, we identified previously unrecognized differences in how VP24 proteins from three ebolavirus species interact with KPNAs. The differences influence IFN inhibitory activity and VP24 stability, affecting the weaker binding bVP24 most dramatically. eVP24 was originally established as a viral immune antagonist that blocks IFN signaling by inhibiting the nuclear import of PY-STAT1 (18, 19) . The discovery of this anti-IFN signaling function correlated with eVP24 binding to the KPNA1 nuclear import factor. KPNA1 had been described as the mediator of PY-STAT1 nuclear import, with this import being mediated via a nonclassical NLS. PY-STAT1 nuclear import is critical to allow PY-STAT1 to stimulate the transcription of interferon-stimulated genes (ISGs) and create an antiviral state (24, 25) . In the presence of excess eVP24, the interaction between KPNA1 and PY-STAT1 was found to be disrupted, thereby preventing ISG expression (18, 19) . Subsequent studies demonstrated that eVP24 and PY-STAT1 can interact with all three members of the NPI-1 subfamily of KPNAs: KPNA1, KPNA5, and KPNA6 (19, 26, 27) .
KPNAs possess an N-terminal importin-beta binding domain, 10 armadillo (ARM) repeats, and a C-terminal CAS binding site. ARM2 to ARM4 and ARM6 to ARM8 are responsible for binding to classical mono-and bipartite basic NLSs, whereas dimerized PY-STAT1 interacts more C-terminally within a region encompassing ARM8 to ARM9 (25) . Mapping studies of KPNA1 indicated that eVP24 binds at a site that partially overlaps the PY-STAT1 ncNLS binding site (19) . Consistent with this observation, an X-ray cocrystal structure demonstrated the interaction of eVP24 with a large binding interface encompassing ARM8 to ARM10 in the C terminus of KPNA5 (21) . Mutagenesis studies, based on the eVP24-KPNA5 structural data, demonstrated that loss of this interaction results in loss of inhibition of IFN-induced PY-STAT1 nuclear import and loss of inhibition of IFN-induced ISG expression. These data, along with data from coIP and in vitro binding studies, all point to a competition binding model of eVP24 antagonism of IFN signaling (21) . Given this model, it was of interest to determine whether affinities of a given VP24 vary between the three different NPI-1 KPNAs. It was also of interest to determine whether VP24s from different ebolavirus species exhibit various degrees of interaction with KPNAs, as this might result in altered degrees of IFN antagonism.
Previous studies established that VP24s from a mouse-adapted EBOV and from REBOV also interacted with members of the NPI-1 subfamily of KPNAs from human and mouse (19) . The mouse-adapted eVP24 amino acid sequence differs by only one amino acid from the parental version of eVP24, whereas rVP24 shares 82% amino acid identity with eVP24 (data not shown). The conservation of KPNA binding activity, despite sequence divergence, suggests a biologically important role for the VP24-KPNA interaction. The coIP assays used to demonstrate these interactions were not quantitative, however, prompting us here to compare KPNA binding affinities using purified, recom-binant versions of eVP24, rVP24, and bVP24. bVP24 was chosen because its sequence is also divergent from that of eVP24, exhibiting 86% amino acid identity to eVP24 (data not shown), and because BDBV exhibits attenuation in human outbreaks and in nonhuman primate models relative to EBOV (3, 4) . Our results demonstrate that the affinities for KPNA1, KPNA5, and KPNA6 are very similar for a given VP24 but that, while eVP24 and rVP24 exhibit similar KPNA binding affinities, bVP24 binding represents lower affinity. Comparable affinities of the VP24 proteins across the NPI-1 KPNAs would allow the virus to block IFN signaling at equal levels regardless of the ratio of NPI-1 family members present in the cell. However, the impaired binding of bVP24 for each KPNA suggested possible functional differences.
Evaluation of the sequences of eVP24 and bVP24 (Fig. 8) identified several differences at the primary sequence level that may impact interactions between KPNAs and VP24 proteins. Our studies show that mutating eVP24 residues to those found in bVP24 results in limited perturbations to binding affinity or IFN antagonism. Importantly, mutation of these same residues to alanine in either eVP24 or bVP24 results in an approximately 10-fold decrease in affinity. Our data are consistent with the following two conclusions. First, the interface between eVP24 and KPNA is highly redundant and is therefore able to accept multiple mutations without significant loss of binding affinity. Second, although the binding interface is redundant and may accommodate multiple interactions, we observed side chain preferences, as the alanine mutations in either eVP24 or bVP24 appear to lose about 10-fold to 15-fold affinity for KPNA.
The different KPNA binding affinities are of functional significance. rVP24 shows modestly higher binding affinity than does eVP24 for each of the KPNAs (Table 1 ). This correlates with very similar capacities of eVP24 and rVP24 for suppression of IFNinduced gene expression in titration studies. In contrast, the significantly lower bVP24 binding affinity with KPNA correlates with slightly impaired suppression of IFN responses at lower concentrations, although binding is sufficient to inhibit IFN-induced gene expression at higher concentrations. VP24 proteins also play other roles over the course of the viral replication cycle. VP24, in cooperation with NP and VP35, promotes the formation of nucleocapsid structures and is necessary for newly formed virus particles to be infectious; VP24 also modulates viral RNA synthesis and serves as a host range determinant, although the impact of VP24 on viral RNA synthesis in the context of EBOV infection has been questioned (8, 10, (12) (13) (14) (15) . Therefore, functional effects of the KPNA interaction on VP24 that extend beyond suppression of IFN responses are of interest. Here, we demonstrate that KPNA has a stabilizing effect on VP24 that may have implications for multiple VP24 functions. The impact of KPNA on stability is most apparent with lower-binding-affinity VP24s. Expressed alone, bVP24 displays a short protein half-life relative to eVP24 and rVP24, as demonstrated by pulse-chase experiments. VP24 half-life is inversely correlated to KPNA binding affinity, as eVP24 proteins with mutations in the KPNA binding interface were also demonstrated to have higher protein turnover than eVP24 or rVP24. Interestingly, when coexpressed with any of the mutant or wild-type eVP24 or bVP24 proteins, only the members of the NPI-1 subfamily of KPNAs had a stabilizing effect on VP24. Conversely, rVP24 appeared to decrease in protein concentration when coexpressed with KPNA5, suggesting that this stabilizing effect could be specific to certain members of the Ebolavirus genus and that KPNA5 may have a unique impact on rVP24. Future studies will need to be performed to determine how KPNA might influence other VP24 functions in the context of virus replication.
An important issue raised by these observations is whether the differences detected impact virulence. While the determinants of filovirus pathogenesis are incompletely defined, robust viral replication and modulation of the innate immune responses are important (14, 28, 29) . For example, VP35 mutations that abrogate its inhibition of IFN production result in attenuation of the virus in vivo and in vitro (28, (30) (31) (32) . In addition, adaptation of EBOV and Marburg virus (MARV) to animal models involves mutations within their respective IFN signaling antagonists, VP24 and VP40, to enhance virulence (15, 16, 19, 29, 33 ). High levels of viral replication would also require robust packaging of the viral genomes to make infectious particles. The substantial similarities between eVP24 and rVP24 in terms of NPI-1 binding affinities and capacity to suppress IFN signaling would argue against the VP24 IFN-antagonist function playing a significant role in virulence differences. The differences between bVP24 and either eVP24 or rVP24 are more intriguing. The lower IFN-antagonist function detected in our transfection studies, which were seen when smaller amounts of bVP24 plasmid were transfected, might result in increased sensitivity to IFNs early in infection, before substantial bVP24 levels have accumulated. If bVP24 is also less stable in infected cells, then this might impact multiple viral functions. It will therefore be important to examine the role of bVP24 during the course of BDBV infection in vivo.
Although filoviruses are primarily of concern as causes of severe human disease, their evolution as zoonotic pathogens has presumably occurred in nonhuman species. As bats have been implicated as the host reservoir for filoviruses, the interaction between KPNA and VP24 most likely evolved in these mammals (34, 35) . While the Egyptian fruit bat (Rousettus aegyptiacus) is believed to act as a reservoir host for Marburg virus, the identities of reservoir hosts for different Ebolavirus species have not been definitively identified (36) . It is likely that the reservoir hosts differ for EBOV, RESTV, and BDBV, which would explain differential interactions with human KPNAs. Taking KPNA5 as an example, the KPNAs are well conserved between humans and bats. However, there are differences, with KPNAs from different bats exhibiting different degrees of amino acid identity. Bats can be divided into two large groups, the microbats and megabats. Human KPNA5 shares 95.9% amino acid identity with KPNA5 from a microbat (Myotis lucifigus) and 98.1% with KPNA5 from a megabat (Pteropus vampyrus) (data not shown). It will be of interest, as reservoir hosts are better defined, to compare VP24-KPNA interactions across different reservoir and nonreservoir mammalian species and determine how these differences in host proteins might influence virulence.
The lack of effective antivirals limits the clinical options available to treat filovirus infections of humans. Because VP24 has roles in innate immune evasion and virus assembly, it is a potential therapeutic target. To date, specific information has been available regarding the structure of eVP24, rVP24, Sudan virus (SUDV) VP24, and eVP24 in complex with KPNA5 (21, 37, 38) . As it is a nonenzymatic protein, therapeutic targeting may require destabilization of VP24 or disruption of functionally important interactions with host or viral factors. In support of the idea of VP24 as a therapeutic target, phosphorodiamidate morpholino oligomers that target VP24 can protect experimentally infected nonhistone proteins (NHPs) from lethal EBOV challenge (39) . Although the eVP24-KPNA5 interface poses challenges due to the fact that it has a large surface area (21) , the data in this study highlight potential synergistic effects of disruption of the interaction. Specifically, one could abrogate the viral block to the antiviral effects of IFNs while also decreasing VP24 stability. The reduced levels of VP24 would therefore impact assembly of virus particles and potentially decrease the infectivity of the virus particles that are produced. For these reasons, efforts to target this interaction are warranted.
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